Biologicals in psoriasis
Keywords:
Biologicals, psoriasisAbstract
During the recent years, a new class of therapeutic agents has been introduced for the treatment of psoriasis and psoriatic arthritis. These agents target different inflammatory mediators involved in the pathogenesis of disease. The focus of this article is on the mechanism of action, side effect profile and dosing of the agents currently in use today for the treatment of psoriasisReferences
Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life and psychological distress in patient with psoriasis: a cluster analysis. J Invest Dermatol 2004; 122: 602-7.
Stern RS, Nijsten T, Feldman SR. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc 2004; 9: 136-9.
Choi J, Koo JY. Quality of life issues in psoriasis J Am Acad Dermatol 2003; 49: S57-61.
Mehlis S, Gordon KB. From laboratory to clinic: Rationale for biologic therapy. Dermatol Clin 2004; 22: 371-7.
Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists guidelines for use of biological intervention in psoriasis 2005. Br J Dermatol 2005; 153: 486-97.
Komeili T, Lowe NJ, Yamuchi PS. Psoriasis. Immunopathogenesis and evolving immunomodulators and systemic therapies; US experiences. Br J Dermatol 2004; 151: 3-15.
Sander DN, Mamelak AJ. Understanding the new clinical landscape for psoriasis. A comparative review of biologics. J Cutan Med Surg 2004; 8: 205-12.
Lowes MA, Lew W, Krueger JG. Current concepts in the immunopathogenesis of psoriasis. Dermatol Clin 2004; 22: 349-69.
Joshi R. Immunopathogenesis of psoriasis. Indian J Dermatol Venereol Leprol 2004; 70: 10-2.
Bonish B, Juillien D, Dutrone Y. Overexpression of CD 1d by keratinocytes in psoriasis and CD 1d dependent IFN gamma production by NK-T cells. J Immunol 2000; 165: 4076-85.
Huang BB, Bonish K, Chaturvedi V. Keratinocyte CDw 60 expression is modulated by both a Th1 type cytokine IFN gamma and Th2 cytokines IL-4 and IL-13. Relevance to psoriasis. J Invest Dermatol 2002; 176: 305-12.
Thappa DV, Laxmisha C. Immunomodulators in the treatment of psoriasis. Indian J Dermatol Venereol Leprol 2004; 70: 1-9.
Lewis V, Finlay AY. Ten years experience of the dermatology life quality index (DLQI). J Invest Dermatol Symp Proc 2004; 9: 169-80.
Krueger GG. Current concepts and review of alefacept in the treatment of psoriasis. Dermatol Clin 2004; 22: 407-26.
Koo J, Khera P. Update on the mechanisms and efficacy of biological therapies for psoriasis. J Dermatol Sci 2005; 38: 75-87.
Krueger GG, Papp KA, Stough DB. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-33.
Lowe NJ, Gonzalez J, Bagel J. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol 2003; 42: 224-30.
Lebowohl M, Christophers E, Langley R. An international randomized, double-blind placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719-27.
Koo J, Rizova E, Freedman D. Combination therapy with alefacept and ultraviolet B light for treatment of psoriasis. Program of the 61st Annual Meeting of the American Academy of Dermatology, 22-26. March 2003; San Francisco, CA, U.S.A., Poster 607.
Leonardi CL. Current concepts and review of efalizumab in the treatment of psoriasis. Dermatol Clin 2004; 22: 427-35.
Lebowohl M, Tyring SK, Hamilton TK et al. A novel targeted T cell modulator, efalizumab for plaque psoriasis. N Engl J Med 2003; 21: 2004-13.
Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized control trial. JAMA 2003; 23: 3073-80.
Leonardi CL, Papp KA, Gordon KB et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol 2005; 52: 425-33.
Menter A, Gordon K, Carey W et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 6: 121-36.
Goldsmith DR, Wagstaff AJ. Etanercept: A review of its use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol 2005; 6: 121-36.
Mease PJ, Goffe BS, Metz J et al. Etanercept in treatement of psoriatic arthritis and psoriasis. A randomized trial. Lancet 2000; 356: 385-90.
Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-32.
Leonardi CL, Powers JL, Matherson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
Papp KA, Tyring S, Lahfa M et al. A global phase III randomized control trial of etanercept in psoriasis: Safety, efficacy and effect of dose reduction. Br J Dermatol 2005; 152: 1304-12.
Chandhari U, Romano P, Mulcahy LD. Efficacy and safety of infliximab monotherapy for plaque type psoriasis: a randomized trial. Lancet 2001; 357: 1842-7.
Kirby B, Marsland AM, Carmichael AJ. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2001; 26: 27-9.
Winterfield L, Menter A. Psoriasis and its treatment with infliximab mediated tumor necrosis factor a blockade. Dermatol Clin 2004; 22: 437-44.
Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque type psoriasis: A randomized double blind placebo controlled trial. J Am Acad Dermatol 2004; 51: 534-42.
Zargari O. Sustained effects of low dose infliximab in combination with methotrexate in the management of chronic recalcitrant psoriasis. Derm Online J 2005; 11: 21.
